Dr. Fred R. Hirsch on Unmet Needs in Lung Cancer

Article

Fred R. Hirsch, MD, PhD, professor of medicine, professor in pathology, University of Colorado, CEO, IASLC, discusses unmet needs in the treatment of lung cancer.

Fred R. Hirsch, MD, PhD, professor of medicine, professor in pathology, University of Colorado, CEO, International Associate for the Study of Lung Cancer (IASLC), discusses unmet needs in the treatment of lung cancer.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background
Photo of a man wearing a suit with a blue tie in front of a dark blue background
4 experts in this video
Related Content
Line illustration of lungs

Opinion: Comprehensive Genomic Profiling Is Vital for Optimizing NSCLC Care

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
July 29th 2025
Article

Oncology nurses can ensure patients with non–small cell lung cancer receive the optimal treatment quickly by understanding comprehensive genomic profiling.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

Lindsay Fischer
November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Graphic of a person with tumors in their right lung

ZEN-3694 Receives FDA Fast Track Status in Metastatic NUT Carcinoma

Russ Conroy
July 23rd 2025
Article

The investigational BET inhibitor is being investigated combined with abemaciclib or cisplatin/etoposide in NUT carcinoma in 2 clinical trials.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Photo of the FDA office's sign

Sunvozertinib Granted FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Bridget Hoyt
July 2nd 2025
Article

Sunvozertinib has received accelerated approval for use in advanced or metastatic non–small lung cancer harboring EGFR exon 20 insertion mutations.

Image of a laptop with the words "FDA Food and Drug Adminstration" visible

Oncology Drugs Approved by the FDA in June

Bridget Hoyt
July 2nd 2025
Article

Oncologic therapies approved in June included indications in genitourinary, lung, hematologic, and head and neck cancers.